Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, raised $83 million by offering 5.5 million shares at $15, selling an additional 500,000 shares at the midpoint of the range of $14 to $16. Milestone...read more
If 2019 is indeed the "year of Uber," then the week ahead can only be the "week of Uber." After years of IPO speculation, Uber (UBER) is expected to raise $8.5 billion at the $47 midpoint, with insiders selling $1.3 billion in the...read more
Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, announced terms for its IPO on Monday.
The Montreal, Canada-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At...read more
Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Montreal, Canada-based company was founded in 2003 and plans to list on...read more
Heart rate condition biotech Milestone Pharmaceuticals prices upsized IPO at $15 midpoint
Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, raised $83 million by offering 5.5 million shares at $15, selling an additional 500,000 shares at the midpoint of the range of $14 to $16. Milestone...read more
US IPO Week Ahead: It's Uber uber alles with biggest IPO in 5 years
If 2019 is indeed the "year of Uber," then the week ahead can only be the "week of Uber." After years of IPO speculation, Uber (UBER) is expected to raise $8.5 billion at the $47 midpoint, with insiders selling $1.3 billion in the...read more
Heart rate condition biotech Milestone Pharmaceuticals sets terms for $75 million IPO
Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, announced terms for its IPO on Monday. The Montreal, Canada-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At...read more
Heart rate condition biotech Milestone Pharmaceuticals files for a $86 million IPO
Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Montreal, Canada-based company was founded in 2003 and plans to list on...read more